alpha lipoic acid in burning mouth syndrome:a randomized double-blind placebo-controlled crossover trial

The effect of alpha lipoic acid in the management of burning mouth syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000251325

Enrollment

Registered

2008-05-19

Start date

2006-06-25

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study was to evaluate the effectiveness of alpha lipoic acid as an alternative in the management of burning mouth syndrome

Interventions

therapy with alpha lipoic acid orally, three capsules of 200 mg per day during 30 days There was a washout period of 20 days

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

burning mouth for 6 months or more, absence of oral mucosal lesions, absence of sistemic conditions whose could produce burning mouth

Exclusion criteria

oral burning under 6 months sistemic diseases (anemia and diabetes) oral mucosal diseases, hypossalivation

Outcome results